We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Artificial Intelligence-driven drug discovery firm Exscientia has formed a strategic research collaboration with Sanofi by signing a licence option agreement in the high-interest area of metabolic disease.